Ambervin
/ Promomed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 19, 2022
Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19
(clinicaltrials.gov)
- P3 | N=313 | Completed | Sponsor: Promomed, LLC
New P3 trial • Infectious Disease • Novel Coronavirus Disease
1 to 1
Of
1
Go to page
1